Postby sdino » Mon Apr 23, 2018 11:37 am
Hi teri3 - In my general laymen terms -
Typically the NCI Team will review all your results, they have a meeting the following Monday and make a decision if you’re a good candidate for the trial or not. Also, If it’s a go, they will request you to be off Chemo at least 30 days prior to surgery. Surgery/recovery at NCI will take approx. 2 to 3 days, then wait 2 more days and do a Apheresis on your blood system.
After surgery, you then go home while they grow billions of cells tumor-infiltrating lymphocytes (TIL). One can go back on chemo. Here is the BIGGEST Catch or Go-No Go: 1. they must grow billions of these cells and 2. The TIL’s (lymphocytes) MUST have genetic mutation(s) (REACTIVE) in them that the tumor cells have or it’s a No Go on trial. If a GO, we then return to NCI in 3 months or so for 1 week of “killer chemo” to destroy the immune system and then rebuild/inject with the new TIL’s. One can become ill from the chemo process and reinjection of new immune system. (4 to 6 week hospital stay @ NCI) This was under the older version of the TIL trial NCT01174121.
There is a New TIL trial NCT03412877 that just opened up this month. Everyone will be looked at for this trial if you meet the criteria. This is very similar to the TIL trial but with the cells coming from peripheral blood and modified with T-cell receptors from tumor TIL. It takes several more months to grow than the old trial and make them REACTIVE in this new trial. What they found in the older trial is that the TILs become old, tired and lethargic. This trial energizes them to continue to fight cancer cells and since they are personalized to you, there is more options or “Keys” for the lymphocytes to lock into her cancer cell genomes (neoantigens) and destroy them. Older TIL trial has an effective rate of 20-25% on other cancers, while this new TIL trial is seeing 40-45% success rate on other cancers.
Caregiver for Wife 54 yrs old
DX:11/16-CC sigmoid colon
Lung Mets: 25+ Bilateral ranging 4mm-5.0cm
MSS, KRAS-G12D; TP53
iTCR TIL Trial NCT03412877 4/19 to 7/19 Off trial, - Sept. 2019 TIL trial NCT01174121
CT Scans: 7/2020 lung met shrinkage 36%, 3 lung mets left, two Liver mets destroyed by TILs
Brain tumor removal 3/2020
CEA:16-11/16; 5 -9/18; 63 -8/19; 1 -1/20; 0.8-5/20